KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) Gross Margin (2016 - 2025)

Pfizer (PFE) has disclosed Gross Margin for 17 consecutive years, with 69.97% as the latest value for Q4 2025.

  • Quarterly Gross Margin changed N/A to 69.97% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 66.68% through Dec 2025, changed N/A year-over-year, with the annual reading at 74.33% for FY2025, 18714.0% up from the prior year.
  • Gross Margin for Q4 2025 was 69.97% at Pfizer, up from 81.55% in the prior quarter.
  • The five-year high for Gross Margin was 79.26% in Q1 2025, with the low at 1090.72% in Q3 2024.
  • Average Gross Margin over 5 years is 30.39%, with a median of 62.98% recorded in 2021.
  • The sharpest move saw Gross Margin plummeted -112202bps in 2024, then soared 100917bps in 2025.
  • Over 5 years, Gross Margin stood at 58.68% in 2021, then grew by 25bps to 73.22% in 2022, then crashed by -264bps to 120.24% in 2023, then crashed by -807bps to 1090.72% in 2024, then soared by 106bps to 69.97% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 69.97%, 81.55%, and 74.22% for Q4 2025, Q3 2025, and Q2 2025 respectively.